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The standardized mean difference (SMD), also referred to simply as effect size, is often used to 
summarize the results of a clinical trial when the outcome measure is continuous. SMD is 
calculated by dividing the difference in the mean scores of the experimental and control groups 
by their standard deviation (SD). One of the major arguments against SMD is that, if the studied 
sample is chosen to be artificially homogeneous and thus have a small SD, SMD can be 
overestimated and thus lose generalizability. On the other hand, smaller SDs raise the chances of 
finding a statistically significant difference. This study examined whether we can increase 
sample homogeneity and decrease SD by raising the severity threshold to enter a clinical trial in 
secondary analyses of individual patient data from three large acute phase schizophrenia trials. 
Raising the baseline threshold on PANSS and BPRS did reduce the SDs at baseline but SMDs at 
endpoint remained by and large constant. This was so because the SDs at endpoint appeared to 
bounce back to their natural values. It is concluded that restricting the entry criteria into 
schizophrenia trials cannot lead to larger SMDs or to smaller sample size necessary to detect an 
efficacy signal. 
 






There is growing and now almost unanimous consensus that all statistical analyses must include 
appropriate reports of effect size estimates in addition to null hypothesis significance test results. 
Effect sizes facilitate understanding of the clinical significance and personal importance of an 
effect (Guyatt et al., 2004) and also allow comparison and synthesis of effects across studies. 
The practice of reporting an “appropriate” effect size index however is not straightforward as 
different indexes each have its own advantages and disadvantages. In the case of continuous 
outcomes, two representative alternatives are “mean difference” (MD) and “standardized mean 
difference” (SMD). MD is a simple difference in the mean scores between two groups, e.g. an 
experimental group and its control group, expressed in the original unit of measurement. SMD, 
by contrast, is MD divided by a standard deviation (SD), usually the pooled SD of the scores of 
the two groups. SMD is therefore a difference in the two group means in SD units. 
SMD enables comparison (and synthesis) of studies using different scales (Higgins and Green, 
2011), and is roughly interpretable (Cohen, 1988), while MD is more intuitive and easier to 
interpret when there is one well-known and dominant scale. More often than not, however, it is 
the case in psychiatry and related disciplines that several validated instruments purport to 
measure the same construct though we may have little idea of how to interpret the results (e.g. 
what 10 points on this scale can mean, or what two-point decrease on that scale may mean) 
(Furukawa et al., 2008; Leucht et al., 2005). Arguably SMD is more interpretable than MD in 
the latter case. 
There are however other arguments against SMD (Baguley, 2009; Greenland et al., 1986), most 
notable of which is the problem arising from range restriction (Bobko et al., 2001). If the sample 
is restricted to a subset of the population of interest, this will influence the variance. If the 
sample is chosen to be particularly homogeneous and thus to have a small SD, SMD can be 
inflated. Such an SMD would probably not be generalizable. On the other hand, in clinical trials, 
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aiming at a larger SMD is often desirable because then type II errors will be reduced and the 
sample size required to detect an efficacy signal can be smaller. Inability to detect statistically 
significant difference between an active arm and a placebo arm is a pressing issue in the field of 
clinical psychopharmacology (Alphs et al., 2012; Kemp et al., 2010). Need to reduce patient 
heterogeneity not only in etiology and pathophysiology but also in manifestation is sometimes 
claimed in this context (Hurko and Ryan, 2005). 
One obvious way to increase sample homogeneity and to decrease SD is to raise the severity 
threshold required of a patient to enter a trial. The present study examines the real-world 
possibility of increasing sample homogeneity and of thus reducing sample variance and its 
effect on SMD, based on individual patient data from large clinical trials of the acute phase 




The study represents post hoc re-analyses of individual patient data from three large randomized 
controlled trials of the acute phase treatment of schizophrenia (Breier et al., 2005; Colonna et al., 
2000; Tollefson et al., 1997). Table 1 shows the characteristics of the three trials including their 
interventions, sample size and eligibility criteria. 
Breier et al and Tellefson et al used the Positive and Negative Syndrome Scale (PANSS) (Kay et 
al., 1987) while Colonna et al the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 
1962) in rating schizophrenic psychopathology. PANSS has 30 items, each rated between 1 and 
7, thus producing the overall score between 30 and 210, whereas BPRS has 18 items only, each 
rated again between 1 and 7, and its total score ranges between 18 and 126. 
In order to model a situation whereby increasingly stricter inclusion criteria are required, we 
restricted the samples to those scoring 50 or higher, 60 or higher, 70 or higher and so on on 
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PANSS, or 40 or higher, 50 or higher and so on on BPRS when the latter was the primary 
outcome measure in the study. We then calculated the SD of PANSS or BPRS scores at baseline 
in order to ascertain that such requirements effectively decreased the SD. 
We examined two outcomes at 4 weeks: the endpoint scores based on the 
last-observation-carried-forward (LOCF) imputation method, and the percent change from 
baseline to LOCFed endpoint. Although all the three studies followed up the participants longer 
than 4 weeks, we chose the 4-week time point as our endpoint because we wanted to minimize 
the possible bias introduced by LOCF due to dropouts that increased substantially after four 
weeks and because the differences between the experimental and control interventions were 
already apparent at this time point. 
We used SPSS 18.0 (SPSS Inc., 2009) for statistical calculations of the original individual 
patient dataset. For SMD, we used Hedge’s g. We calculated Kendall’s tau to examine the 
correlation between baseline severity threshold and SDs or SMDs. 
 
3. RESULTS 
3.1. Requiring higher baseline threshold effectively decreased SD at baseline. 
Table 2 shows the SDs at baseline when we restricted the samples to those scoring 50 or higher, 
60 or higher, 70 or higher and so on on PANSS in the case of Tollefson et al’s and Breier et al’s 
trials, or 40 or higher, 45 or higher, 50 or higher and so on on BPRS in the case of Colonna et 
al’s trial. It is evident that baseline SDs got progressively smaller as we required a higher and 
higher threshold as an eligibility criterion for entry into the study. Kendall’s tau correlation 
coefficients between the required thresholds and the SDs were all close to -1.0 and highly 




3.2. But effect size remained stable. 
However, as the baseline SDs decreased with higher and higher inclusion thresholds required, 
SMDs in terms of LOCFed endpoint scores or in terms of LOCFed %change scores remained 
by and large constant (Table 3, Figures 1 and 2). Kendall’s tau correlation coefficients between 
the baseline thresholds and the SMDs were all small to moderate, and not statistically 
significant. Figures 2 and 3 demonstrate clearly that 95%CI of these SMDs overlapped with 
each other. 
This happened so apparently because the SDs of endpoint scores tended to increase and those 
of %change remained largely stable, as the baseline inclusion thresholds were raised and the 
baseline SDs became smaller (Table 2). 
 
4. DISCUSSION 
Raising the entry threshold, an obvious method to increase sample homogeneity, did reduce the 
SDs at baseline but either increased or did not change SDs at endpoint. To our own great 
surprise, SMDs at endpoint remained by and large stable. 
In other words, although the baseline SDs were effectively reduced by manipulating the entry 
criterion, it was as if the endpoint SDs bounced back to the natural SDs. This may therefore 
represent the regression towards the mean of the variability of symptom severity among a group 
of patients with schizophrenia. For example, among the 18 trials that were included in Cochrane 
reviews for olanzapine or amisulpride, the SDs of PANSS total scores at endpoint at the end of 
the acute phase treatment ranged between 19.7 and 30.2 (mean=24.5) and that for BPRS total 
scores ranged between 4.4 and 15.1 (mean=12.3) (Duggan et al., 2005; Mota et al., 2002). The 
endpoint SDs observed in various subsamples in our study were approximately comparable to 
these other studies. The larger SD of endpoint scores among those with severer 
psychopathology is also understandable because they may show greater heterogeneity of 
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response to treatment, while the same appears to be cancelled when we take %change as the 
outcome measure. 
The above-described pattern was most conspicuous with the two olanzapine trials, whereas 
there was a greater fluctuation in estimates of SMDs in the amisulpride trial. It is to note in this 
connection that the first two trials used the PANSS whereas the last used the BPRS. Whether the 
greater fluctuation is due to the smaller sample size of the last trial or to the instability of the 
measuring instrument it used, namely BPRS, is yet to be researched. As noted above, the SDs of 
endpoint BPRS scores appeared to show greater variability than those of endpoint PANSS 
scores among the trials included in the Cochrane reviews (Duggan et al., 2005; Mota et al., 
2002) too. 
There are obvious limitations to this small study. Firstly, it used individual patient data from 
three trials examining olanzapine, amisulpride, ziprasidone and holopridol in the acute phase 
treatment of schizophrenia only. Whether the observed results apply to other antipsychotics and 
to other mental disorders is open to future studies. The constant SMDs regardless of baseline 
symptom severity observed in our study may be all the more noteworthy when we consider a 
number of recent studies of major depression that claimed that the effects of both drugs and 
psychotherapies were obvious only among the more severely depressed patients (Driessen et al., 
2010; Fournier et al., 2010; Kirsch et al., 2008). Secondly, the current study does not rule out 
the possibility of other methods to increase sample homogeneity to produce smaller SDs and 
hence larger SMDs. Aetiological and/or pathophysiological subtyping of schizophrenia may be 
a better way to increase sample homogeneity than a symptomatological approach although we 
have not been very successful in either approach up to now. 
In conclusion, restricting the entry criteria into schizophrenia trials does not appear to be able to 
increase SMD or thus to decrease the necessary sample size to detect a statistically significant 
difference in a clinical trial. SMD may be a more generalizable and reproducible index of 
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Figure 1. Changes in endpoint SMDs, based on the required severity threshold 
 






Table 1. Characteristics of the three included trials 
 
Study Antipsychotic drugs 
and daily dosage (mg) 
Sample 
size 
Baseline threshold required Baseline severity 
mean (Range) 






36 or higher on BPRS 
(scored 1-7) 
and/or intolerant of current 
antipsychotic therapy 
excluding haloperidol 
90.9 (Range: 30-166) 
on PANSS 




42 or higher on BPRS 
(scored 1-7) 
and 4 or higher on at least 
one positive symptom item 
of PANSS 
and 4 or higher CGI 
Severity 
100.9 (Range: 
63-168) on PANSS 




4 or higher on at least two 
of the four BPRS positive 
items (scored 1-7) 
56.2 (Range: 30-104) 
on BPRS 
BPRS: Brief Psychiatric Rating Scale 
CGI: Clinical Global Impression 





Table 2. Setting lower limits: SDs at baseline, and SDs and SMDs at endpoint 
 
 Entry threshold SD of baseline 
scores 






>=50 (n=1982) 19.2 22.6 -0.20 
>=60 (n=1939) 18.7 22.4 -0.20 
>=70(n=1744) 17.3 22.3 -0.19 
>=80 (n=1387) 15.6 22.6 -0.16 
>=90 (n=974) 14.2 23.4 -0.13 
>=100 (n=593) 12.7 24.3 -0.27 
>=110 (n=340) 11.5 26.0 -0.25  
Kendall’s tau -1.00, p<0.001 0.68, p=0.03 0.00, ns 
Olanzapine vs 
ziprasidone 
>=50 (n=545) 20.2 23.6 -0.31  
>=60 (n=545) 20.2 23.6 -0.31  
>=70 (n=536) 19.9 23.7 -0.31 
>=80 (n=473) 18.5 24.0 -0.30 
>=90 (n=372) 17.2 25.0 -0.28 
>=100 (n=244) 15.6 27.0 -0.37 
>=110 (n=156) 13.7 28.0 -0.29 
Kendall’s tau -0.98, p=0.002 0.98, p=0.002 0.31, ns 
Amisulpride vs 
haloperidol 
>=40 (n=448) 11.5 13.1 -0.27 
>=45 (n=401) 10.7 14.9 -0.25 
>=50 (n=330) 9.8 15.0 -0.16 
>55 (n=252) 8.7 15.4 -0.30 
>=60 (n=177) 7.7 15.2 -0.09 
>65 (n=125) 6.8 15.1 -0.10 






Table 3. Setting upper limits: SDs at baseline, and SDs and SMDs at endpoint 
 
 Entry threshold SD of baseline 
scores 






<=130 (n=1927) 17.3 21.1 -0.18 
<=120 (n=1846) 16.0 20.3 -0.17 
<=110 (n=1670) 13.9 19.2 -0.18 
<=100 (n=1427) 11.9 18.2 -0.16 
<=90 (n=1064) 10.0 16.9 -0.25 
<=80 (n=643) 8.0 15.3 -0.33 
Kendall’s tau -1.00, p<0.001 -1.00, p<0.001 -0.41, ns 
Olanzapine vs 
ziprasidone 
<=130 (n=493) 15.2 20.5 -0.27 
<=120 (n=450) 13.0 19.7 -0.27 
<=110 (n=394) 10.8 18.6 -0.30 
<=100 (n=309) 8.7 17.7 -0.24 
<=90 (n=184) 6.4 17.0 -0.31 
<=80 (n=75) 4.1 13.5 -0.45 
Kendall’s tau -1.00, p<0.001 -1.00, p<0.001 -0.56, ns 
Amisulpride vs 
haloperidol 
<=80 (n=472) 11.6 14.1 -0.23 
<=75 (n=444) 10.4 13.7 -0.22 
<=70 (n=413) 9.4 13.4 -0.21 
<=65 (n=371) 8.3 12.5 -0.16 
<=60 (n=322) 7.2 11.5 -0.20 
<=55 (n=249) 6.0 10.8 -0.18 
<=50 (n=173) 5.1 10.1 -0.16 
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Figure 1. Endpoint SMDs according to various lower severity thresholds 











n=1982 1939 1744 1387 974 593 340 











n=545 545 536 473 372 244 156 















Figure 2. Endpoint SMDs according to various upper severity threshold 
2a. Olanzapine vs haloperidol 
 
2b. Olanzapine vs ziprasidone 
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